B Seruga1, P C Hertz1, L W Le1, I F Tannock2. 1. Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada. 2. Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada. Electronic address: ian.tannock@uhn.on.ca.
Abstract
BACKGROUND: Drug development in cancer is costly and may be directed toward 'profitable' cancers of the more developed regions (MDR) as compared with those of the less developed regions (LDR) of the world. Here, we describe drug development in relation to cancer type and geographic location. MATERIALS AND METHODS: We reviewed phase II and III clinical trials evaluating new cancer drugs, which were registered from January to June 2008. Correlations were sought between the number of clinical trials and incidence, mortality and prevalence of the cancers studied (obtained from GLOBOCAN 2002) and stratified by region of the world. RESULTS: We identified 399 newly registered trials. Most trials (N = 229, 57%) were sponsored by industry. The most common types of cancer studied were breast 73 (18%), lung 57 (14%), prostate 44 (11%) and colorectal 28 (7%). In MDR, incidence, mortality and prevalence correlated significantly (Pearson r = 0.80, 0.73 and 0.63; P < or = 0.01) with the number of all registered clinical trials, whereas in LDR, only prevalence showed significant association (Pearson r = 0.55; P = 0.03) with the number of trials for a given type of cancer. CONCLUSION: Lethal cancers that are common in the LDR (e.g. stomach, liver and esophageal cancers) deserve greater emphasis for drug development.
BACKGROUND: Drug development in cancer is costly and may be directed toward 'profitable' cancers of the more developed regions (MDR) as compared with those of the less developed regions (LDR) of the world. Here, we describe drug development in relation to cancer type and geographic location. MATERIALS AND METHODS: We reviewed phase II and III clinical trials evaluating new cancer drugs, which were registered from January to June 2008. Correlations were sought between the number of clinical trials and incidence, mortality and prevalence of the cancers studied (obtained from GLOBOCAN 2002) and stratified by region of the world. RESULTS: We identified 399 newly registered trials. Most trials (N = 229, 57%) were sponsored by industry. The most common types of cancer studied were breast 73 (18%), lung 57 (14%), prostate 44 (11%) and colorectal 28 (7%). In MDR, incidence, mortality and prevalence correlated significantly (Pearson r = 0.80, 0.73 and 0.63; P < or = 0.01) with the number of all registered clinical trials, whereas in LDR, only prevalence showed significant association (Pearson r = 0.55; P = 0.03) with the number of trials for a given type of cancer. CONCLUSION: Lethal cancers that are common in the LDR (e.g. stomach, liver and esophageal cancers) deserve greater emphasis for drug development.
Authors: C S Pramesh; Rajendra A Badwe; Nirmala Bhoo-Pathy; Christopher M Booth; Girish Chinnaswamy; Anna J Dare; Victor Piana de Andrade; David J Hunter; Satish Gopal; Mary Gospodarowicz; Sanjeeva Gunasekera; Andre Ilbawi; Sharon Kapambwe; Peter Kingham; Tezer Kutluk; Nirmal Lamichhane; Miriam Mutebi; Jackson Orem; Groesbeck Parham; Priya Ranganathan; Manju Sengar; Richard Sullivan; Soumya Swaminathan; Ian F Tannock; Vivek Tomar; Verna Vanderpuye; Cherian Varghese; Elisabete Weiderpass Journal: Nat Med Date: 2022-04-19 Impact factor: 87.241
Authors: Priya Ranganathan; Girish Chinnaswamy; Manju Sengar; Durga Gadgil; Shivakumar Thiagarajan; Balram Bhargava; Christopher M Booth; Marc Buyse; Sanjiv Chopra; Chris Frampton; Satish Gopal; Nick Grant; Mark Krailo; Ruth Langley; Prashant Mathur; Xavier Paoletti; Mahesh Parmar; Arnie Purushotham; Douglas Pyle; Preetha Rajaraman; Martin R Stockler; Richard Sullivan; Soumya Swaminathan; Ian Tannock; Edward Trimble; Rajendra A Badwe; C S Pramesh Journal: Lancet Oncol Date: 2021-06-30 Impact factor: 54.433
Authors: Janice C Wong; Kimberly A Fernandes; Shubarna Amin; Zarnie Lwin; Monika K Krzyzanowska Journal: Global Health Date: 2014-12-13 Impact factor: 4.185